Comparison of 0.1% Bromfenac Sodium and 0.1% Pemirolast Potassium for the Treatment of Allergic Conjunctivitis

• Published in: Japanese journal of ophthalmology Vol. 48; no. 6; pp. 587 - 590
• Main Authors: Miyake-Kashima, Minori, Takano, Yoji, Tanaka, Mari, Satake, Yoshiyuki, Kawakita, Tetsuya, Dogru, Murat, Asano-Kato, Naoko, Fukagawa, Kazumi, Fujishima, Hiroshi
• Format: Journal Article
• Language: English
• Published: Japan Springer Nature B.V 01.11.2004
• Subjects: Adolescent; Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal - administration & dosage; Anti-Inflammatory Agents, Non-Steroidal - therapeutic use; Benzophenones - administration & dosage; Benzophenones - therapeutic use; Bromobenzenes - administration & dosage; Bromobenzenes - therapeutic use; Child; Conjunctivitis, Allergic - blood; Conjunctivitis, Allergic - diagnosis; Conjunctivitis, Allergic - drug therapy; Female; Histamine Antagonists - administration & dosage; Histamine Antagonists - adverse effects; Humans; Immunoglobulin E - blood; Male; Middle Aged; Ophthalmic Solutions; Pyridines - administration & dosage; Pyridines - therapeutic use; Pyrimidinones - administration & dosage; Pyrimidinones - therapeutic use; Safety; Treatment Outcome
• ISSN: 0021-5155; 1613-2246
• DOI: 10.1007/s10384-004-0127-2

We compared the efficacy of a new nonsteroidal antiinflammatory drug (NSAID) eye drop, 0.1% bromfenac sodium (Bromfenac), with that of an antiallergic agent, 0.1% pemirolast potassium (Pemirolast), in the treatment of seasonal allergic conjunctivitis in Japanese patients. Twenty-two subjects with seasonal allergic conjunctivitis were enrolled in the study. One eye was treated with Bromfenac eye drops and the contralateral eye was treated with Pemirolast eye drops for 1 week. Subjective ocular symptoms and objective ocular signs evaluated by slit-lamp examination were scored and recorded before and after treatment. Both drugs significantly decreased ocular signs after 1 week, but not symptoms. No significant differences in subjective symptoms or objective signs were observed between the two drugs. Ten patients (45.5%) selected Bromfenac as more effective, nine patients (40.9%) selected Pemirolast, and three patients found no difference in efficacy between the two drugs. Bromfenac sodium is as safe and effective for the treatment of allergic conjunctivitis as pemirolast potassium.